Publications by authors named "Sornaraja Thasma"
Article Synopsis
- Nicotinamide mononucleotide (NMN) boosts blood levels of nicotinamide adenine dinucleotide (NAD), which decreases with age, but the best dose of NMN isn't yet known.
- A clinical trial with 80 healthy adults aged 40-65 tested daily doses of NMN (300mg, 600mg, 900mg), leading to significant dose-dependent increases in NAD levels and improvements in physical and mental health measures, including walking distance and quality of life scores.
- Variability in how individuals respond to NMN suggests that monitoring NAD levels can help determine personalized dosages for more effective supplementation.*
In animal studies, β-nicotinamide mononucleotide (NMN) supplementation increases nicotinamide adenine dinucleotide (NAD) concentrations and improves healthspan and lifespan with great safety. However, it is unclear if these effects can be transferred to humans. This randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial included 80 middle-aged healthy adults being randomized for a 60-day clinical trial with once daily oral dosing of placebo, 300 mg, 600 mg, or 900 mg NMN.
View Article and Find Full Text PDFObjective: Recruiting into clinical trials on time and on target is a major challenge and yet often goes unreported. This study evaluated the adjustment to procedures, recruitment and screening methods in two multi-centre pharmaceutical randomised controlled trials (RCTs) for hearing-related problems in adults.
Design: Recruitment monitoring and subsequent adjustment of various study procedures (e.